Bayer, a world pharmaceutical giant, has expanded its aid donations for Ebola patients in Liberia and Sierra Leone with additional drugs.
The company is supplementing its previous donation of medications with a further delivery of the antibiotic ciprofloxacin to a value of1.15 million Euros.
This medication does not treat the Ebola infection itself, but can be used for life-threatening secondary bacterial infections.
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas.
According to news reports, Bayer will distribute to two clinics in Monrovia while 'Action Medeor' the largest German-based Aid Organization specialized in medicines will distribute to surrounding health centers.
The report notes that Bayer has already donated ciprofloxacin in various dosages and modes of administration to a value of approximately 2.57 million Euros to treat patients infected with the Ebola
This donation of medication for treating African Ebola patients with a total value of over3.7 million Euros is one of the largest in Bayer’s history.
“We are again increasing our commitment to helping the people affected and making our contribution to stemming the spread of the Ebola epidemic,” says Dr. Marijn Dekkers, Chairman of the Board of Management of Bayer AG.
“With this donation, we are fulfilling our corporate social responsibility as a global health company,” he added.